Mezzion Pharma KRX:140410KOSDAQ
메지온 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days2
DART filings, 7 days0
Articles tracked2since Sep 11
In Q2 2026, Mezzion Pharma reported revenue of ₩2.2bn, up 26.2% year on year, and an operating loss of ₩4.5bn. Mezzion Pharma (메지온) appeared in 2 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 26 with 2 articles.
Filing signals 4 quarters of losses Screener
Mezzion Pharma quarterly results consolidated, KRW
| Quarter | Operating profit | Net income |
|---|---|---|
| Q2 2026 | −₩4.5bn margin −206.3% | ₩7.7bn |
| Q1 2026 | −₩4.6bn | – |
| Q4 2025 derived | −₩5.1bn | – |
| Q3 2025 | −₩4.7bn | – |
| Q2 2025 | −₩3.5bn margin −203.4% | −₩1.9bn |
| Q1 2025 | −₩3.5bn | – |
| Q4 2024 derived | −₩4.0bn | – |
| Q3 2024 | −₩1.7bn | – |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Mezzion Pharma top stories 2 weeks, by number of outlets
- 1
Latest Mezzion Pharma news Korean headlines
-
메지온, 신장병 신약에 별도 ‘가격표’…美법인 세워 M&A까지 노린다
1 more on this story · 1 outlets
- 메지온, 신장병 신약에 별도 ‘가격표’…美법인 세워 M&A까지 노린다이데일리 · Sep 26 11:01